Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cervical mucus may hold key to better IVF timing

NCT ID NCT04619524

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is collecting cervical mucus from 476 women undergoing IVF or frozen embryo transfer. Researchers will analyze the proteins in the mucus to find markers that indicate when the uterus is most receptive to an embryo. By comparing samples from women who become pregnant with those who do not, they hope to develop a test that helps doctors choose the optimal time for embryo transfer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple test to determine the best time for embryo transfer, potentially improving IVF success rates.
What could go wrong
This is an observational study, not a treatment trial. It may not identify reliable biomarkers, and any future test would require further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 476 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 36 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Arm A - stimulated cycle: * female aged less than 37 years (maximally 36y + 364d) * no smoker * normal menstrual cycles lasting between 25 to 35 days * had been infertile for less than five years * normal responder * fewer than three failed cycles of assisted reproduction treatment, including fresh IVF/ intracytoplasmic sperm injection (ICSI) embryo transfer cycles and/or frozen-thawed embryo transfer cycles * sperm obtained through ejaculation * spermiogram more than 5 million sperm/mL * BMI 19-29 kg/m2 * follicle stimulating hormone (FSH) \< 10 IU/L on the third day * basal antral follicle count of 5-15 * undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol * informed consent Exclusion Criteria - Arm A - stimulated cycle: * genetic disease * metabolic and/or endocrine disorders * polycystic ovary syndrome (defined by the Rotterdam criteria) * women with prior diagnosis of endometriosis or adenomyosis * previous gynecological/pelvic surgery except for salpingectomy * repeated spontaneous abortions (two or more) * previously less than 5 oocytes and/or serum anti-Mullerian hormone value \< 1.0 mIU/ml or more than 20 oocytes, milli-International unit (mIU) * previous ovarian hyperstimulation syndrome (OHSS) * presence of any structural abnormality of the reproductive system * donor oocyte cycles * severe male factor infertility \< 5 million sperm/mL * low response to stimulation * endometrium \< 8 mm at the day of human chorionic gonadotropin (hCG) or ET * number of retrieved oocytes 5 - 20 * low fertilization capacity (rate of fertilization \< 20% and late ICSI following IVF fertilization failure) * OHSS * IVF cycle cancelled before ET * other than easy one high-quality blastocyst transfer (at least grade 3BB) Inclusion criteria - Arm B - substituted cycle: * female aged less than 37 years (maximally 36y + 364d) * no smoker * normal menstrual cycles lasting between 25 to 35 days * had been infertile for less than five years * normal responder at stimulation * fewer than three failed cycles of assisted reproduction treatment, including fresh IVF/ intracytoplasmic sperm injection (ICSI) embryo transfer cycles and/or frozen-thawed embryo transfer cycles * sperm obtained through ejaculation * spermiogram more than 5 million sperm/mL * BMI 19-29 kg/m2 * FSH \< 10 IU/L on the third day * undergoing the same routine estrogen/progesterone substituted cycle * informed consent Exclusion criteria - Arm B - substituted cycle: * genetic disease * metabolic and/or endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders * polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia * women with prior diagnosis of endometriosis or adenomyosis * previous gynecological/pelvic surgery except for salpingectomy * repeated spontaneous abortions (two or more) * previously less than 5 oocytes and/or serum anti-Mullerian hormone value \< 0.5 mIU/ml in the stimulated cycle * previous OHSS * presence of any structural abnormality of the reproductive system * severe male factor infertility \< 5 million sperm/mL in the stimulated cycle * number of retrieved oocytes 5 - 20 in the stimulated cycle * low fertilization capacity (rate of fertilization \< 20% and late ICSI following IVF fertilization failure) * endometrium less than 8 mm at the day of thawing and transfer indication * thawed blastocyst cycle cancelled before ET * other than easy one best quality frozen/thawed blastocyst transfer (at least grade 3BB)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embryo transfer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brno University Hospital

    RECRUITING

    Brno, South Moravian, 62500, Czechia

  • University Hospital Olomouc

    RECRUITING

    Olomouc, 77900, Czechia

  • University Hospital Olomouc

    RECRUITING

    Olomouc, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.